The Rosen Law Firm announces that it is investigating potential securities claims against Arrowhead Research Corp. (NASDAQ:ARWR) resulting from allegations that the Company may have issued materially misleading business information to the investing public.

On October 8, 2014, Arrowhead Research released disappointing data from its experimental hepatitis B therapy ARC-520. On that same day, an article published on reported that Arrowhead Research CEO Chris Anzalone and his team knew for months that ARC-520 dosed at 1 mg/kg and 2 mg/kg yielded 0.2-log and 0.3-log reductions in hepatitis B viral load. Yet, Arrowhead executives led investors to believe that ARC-520 was more potent and achieved viral load reductions in the range of 0.7 log or higher. On this news, shares of Arrowhead Research fell $5.48 per share, or over 43%, to close at $7.03 per share on October 8, 2014.

The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Arrowhead Research shareholders as a result of this adverse information. If you purchased Arrowhead Research stock on or before October 8, 2014, please visit the website at for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at or

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Copyright Business Wire 2010